Both high-dose interleukin-2 (IL-2) [2] and, more recently, combination immune checkpoint blockade with antibodies targeting programmed cell death-protein 1 (PD1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4) [3] have been associated with complete radiographic responses in 5–9% of RCC patients. Here, CTLA4 is linked to renal cell carcinoma.